The development and appraisal of a tool designed to find patients harmed by falsely labelled, falsified (counterfeit) medicines.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
De Bono, Virgilio
MetadataShow full item record
CitationThe development and appraisal of a tool designed to find patients harmed by falsely labelled, falsified (counterfeit) medicines. 2017, 17 (1):419 BMC Health Serv Res
ÚtdrátturFalsely labelled, falsified (counterfeit) medicines (FFCm's) are produced or distributed illegally and can harm patients. Although the occurrence of FFCm's is increasing in Europe, harm is rarely reported. The European Directorate for the Quality of Medicines & Health-Care (EDQM) has therefore coordinated the development and validation of a screening tool.
The tool consists of a questionnaire referring to a watch-list of FFCm's identified in Europe, including symptoms of their use and individual risk factors, and a scoring form. To refine the questionnaire and reference method, a pilot-study was performed in 105 self-reported users of watch-list medicines. Subsequently, the tool was validated under "real-life conditions" in 371 patients in 5 ambulatory and in-patient care sites ("sub-studies"). The physicians participating in the study scored the patients and classified their risk of harm as "unlikely" or "probable" (cut-off level: presence of ≥2 of 5 risk factors). They assessed all medical records retrospectively (independent reference method) to validate the risk classification and documented their perception of the tool's value.
In 3 ambulatory care sites (180 patients), the tool correctly classified 5 patients as harmed by FFCm's. The positive and negative likelihood ratios (LR+/LR-) and the discrimination power were calculated for two cut-off levels: a) 1 site (50 patients): presence of two risk factors (at 10% estimated health care system contamination with FFCm's): LR + 4.9/LR-0, post-test probability: 35%; b) 2 sites (130 patients): presence of three risk factors (at 5% estimated prevalence of use of non-prescribed medicines (FFCm's) by certain risk groups): LR + 9.7/LR-0, post-test probability: 33%. In 2 in-patient care sites (191 patients), no patient was confirmed as harmed by FFCm's. The physicians perceived the tool as valuable for finding harm, and as an information source regarding risk factors.
This "decision aid" is a systematic tool which helps find in medical practice patients harmed by FFCm's. This study supports its value in ambulatory care in regions with health care system contamination and in certain risk groups. The establishment of systematic communication between authorities and the medical community concerning FFCm's, current patterns of use and case reports may sustain positive public health impacts.
Lu00FDsingTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files
RightsArchived with thanks to BMC health services research
- Fighting trafficking of falsified and substandard medicinal products in Russia.
- Authors: Fayzrakhmanov NF
- Issue date: 2015
- Substandard and falsified medical products are a global public health threat. A pilot survey of awareness among physicians in Sweden.
- Authors: Funestrand H, Liu R, Lundin S, Troein M
- Issue date: 2019 Mar 1
- [European Network of Official Medicines Control Laboratories : International OMCL Working Group Combating Counterfeit and other Illegal Medicines].
- Authors: Wanko R, Unkelbach U
- Issue date: 2017 Nov
- Legal aspects of counteracting the trafficking of falsified medicines in the european union.
- Authors: Pashkov V, Soloviov A, Olefir A
- Issue date: 2017
- Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
- Authors: Iloh GU, Akodu BA, Emeka EA, Obi IV
- Issue date: 2021 Nov 30